Eris Lifesciences · NSE: ERIS · BSE: 540596
Q3 FY22 results · Oct–Dec 2021
Eris Lifesciences reported revenue from operations of ₹304.63 crore (up 6.1% from Q3 FY21) and net profit of ₹104.06 crore (up 17.4% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 304.63 | 287.13 | +6.1% | 322.66 | −5.6% |
| Other income | 5.84 | 3.43 | +70.1% | 7.65 | −23.8% |
| Total income | 310.47 | 290.56 | +6.9% | 330.31 | −6.0% |
| Profit before tax | 114.32 | 97.37 | +17.4% | 132.29 | −13.6% |
| Net profit for the period | 104.06 | 88.63 | +17.4% | 119.71 | −13.1% |
| EPS, basic (₹) | 7.66 | 6.52 | +17.5% | 8.81 | −13.1% |
| Net margin (%) | 34.2 | 30.9 | 37.1 |
Standalone
- Filed with BSE
- 28 Jan 2022, 19:12 IST
- Board meeting
- 28 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE